Agreement between different linear-combination modelling algorithms for short-TE proton spectra

Helge J. Zöllner[1,2,*], Michal Považan[1,2], Steve C. N. Hui[1,2], Sofie Tapper[1,2], Richard A. E. Edden[1,2], Georg Oeltzschner[1,2]

[1] *Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States*

[2] *F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, United States*

***Corresponding author:**

Georg Oeltzschner, Ph.D.

Division of Neuroradiology, Park 367G

The Johns Hopkins University School of Medicine

600 N Wolfe St

Baltimore, MD 21287

goeltzs1@jhmi.edu

Word count: 4808

Figure count: 6

Table count: 2

Keywords: MRS, linear-combination modelling, short-echo-time spectra, LCM

Abstract

Purpose

Short-TE proton MRS is used to study metabolism in the human brain. Common analysis methods model the data as linear combination of metabolite basis spectra. This large-scale multi-site study compares the levels of the four major metabolite complexes in short-TE spectra estimated by three linear-combination modelling (LCM) algorithms.

Methods

277 short-TE spectra from a recent multi-site study were pre-processed with the Osprey software. The resulting spectra were modelled with Osprey, Tarquin and LCModel, using the same three vendor-specific basis sets (GE, Philips, and Siemens) for each algorithm. Levels of total N-acetylaspartate (tNAA), total choline (tCho), myo-inositol (mI), and glutamate+glutamine (Glx) were quantified with respect to total creatine (tCr).

Results

Group means and CVs of metabolite estimates agreed well for tNAA and tCho across vendors and algorithms, but substantially less so for Glx and mI, with mI systematically estimated lower by Tarquin. The cohort mean correlation coefficient for all pairs of LCM algorithms across all datasets and metabolites was $\overline{\mathbf{R}^2}$ =0.39, indicating generally only moderate agreement of individual metabolite estimates between algorithms. There was a significant correlation between local baseline amplitude and metabolite estimates (cohort mean $\overline{\mathbf{R}^2}$ =0.10).

Conclusion

While mean estimates of major metabolite complexes broadly agree between linear-combination modelling algorithms at group level, correlations between algorithms are only weak-to-moderate, despite standardized pre-processing, a large sample of young, healthy and cooperative subjects, and high spectral quality. These findings raise concerns about the comparability of MRS studies, which typically use one LCM software and much smaller sample sizes.

Introduction

Proton MRS allows in-vivo research studies of metabolism[1,2]. Single-voxel MR spectra from the human brain are frequently acquired using PRESS localization[3] , and can be modelled to estimate metabolite levels. Accurate modelling is hampered by poor spectral resolution at clinical field strengths, and for short-echo-time spectra, metabolite signals overlap with a broad background consisting of fast-decaying macromolecule and lipid signals. Linear-combination modelling (LCM) of the spectra maximizes the use of prior knowledge to constrain the model solution, and is recommended by recent consensus[4]. LCM algorithms model spectra as a linear combination of (metabolite and macromolecular (MM)) basis functions, and typically also include terms to account for smooth baseline fluctuations.

Several LCM algorithms are available to quantify MR spectra (**Table 1** describes some of the most widely used: Osprey[5], INSPECTOR[6], Tarquin[7], AQSES[8], Vespa[9], QUEST[10], LCModel[11]). The implementations (open-source vs. compiled 'black-box'), modelling approaches (modelling domain and baseline model), and their licensure practices are diverse.

***Table 1**. Overview of linear-combination modelling algorithms. The domain (time TD or frequency FD) of modelling and the baseline model approach are specified. *Citations reported from Google Scholar on July 29, 2020.*

Name	Modelling Domain, Baseline approach	Cost	Code Availability	Published	Citations*
Osprey	FD, spline baseline	free	open	2020	1
INSPECTOR	FD, 1st-order polynomial	free	open	2018	0
Tarquin	TD, smooth baseline	free	open	2011	252
AQSES (jMRUI)	TD, spline baseline	free	closed	2007	140
Vespa	FD, wavelet baseline	free	open	2006	68
QUEST (jMRUI)	TD, spline baseline	free	closed	2004	305
LCModel	FD, spline baseline	$13,300	closed	1992	3454

Surprisingly few studies have compared the performance of different LCM algorithms. Cross-validation of quantitative results has almost exclusively been performed in the context of benchmarking new algorithms against existing solutions. In-vivo comparisons are often limited to

small sample sizes, whether analyzing spectra from animal models[7,12,13] or human subjects[7,8,12]. To the best of our knowledge, two exceptions compared the LCM performance of different algorithms in rat brain[14] and human body[15], respectively. Most studies report good agreement between results from different algorithms, inferring this from group-mean comparisons, or observing that differences between clinical groups are consistent regardless of the algorithm applied[14,16]. Correlations of estimates from different algorithms are rarely reported; however, a high correlation between LCModel and Tarquin results was found in the rat brain at ultra-high field[14]. Despite the fact that LCM has been used to analyze thousands of studies (Table 1), a comprehensive assessment of the agreement between the algorithms is lacking, and the relationship between the choice of model parameters and quantitative outcomes is poorly understood. To begin to address this gap, we conducted a large-scale comparison of short-TE in-vivo MRS data using three LCM algorithms with standardized pre-processing. While recent expert consensus recommends using measured MM background spectra, data for different sequences are not broadly available or integrated in LCM software. This manuscript investigates current common practice, and therefore all models included simulated MM basis functions. We compared group-mean quantification results of four major metabolite complexes from each LCM algorithm, performed between-algorithm correlation analyses, and investigated local baseline power and creatine modelling as potential sources of differences between the algorithms.

Methods

Participants & acquisition

277 single-voxel short-TE PRESS datasets from healthy volunteers acquired in a recent multi-site-study[17] were included in this analysis. Data were acquired at 25 sites (with up to 12 subjects per site) on scanners from three different vendors (GE: 8 sites with n = 91; Philips: 10 sites with n = 112; and Siemens: 7 sites with n = 74) with the following parameters: TR/TE = 2000/35 ms; 64 averages; 2, 4 or 5 kHz spectral bandwidth; 2048-4096 data points; acquisition time = 2.13 min; 3×3×3 cm^3 voxel in the medial parietal lobe. Reference spectra were acquired with similar parameters, but without water suppression and 8-16 averages (for more details, please refer to [17]). Data were saved in vendor-native formats (GE P-files, Philips .sdat, and Siemens TWIX). In the initial study[18], written informed consent was obtained from each participant and the study was approved by local institutional review boards. Anonymized data were shared securely and analyzed at Johns Hopkins University with local IRB approval. Due to site-based data privacy guidelines, only a subset of these data (GE: 7 sites with n = 79; Philips: 9 sites with n = 100; and Siemens: 4 sites with n = 48) is publicly available[19].

Data pre-processing

MRS data were pre-processed in Osprey[5], an open-source MATLAB toolbox, following recent peer-reviewed pre-processing recommendations[2], as summarized in **Figure 1A**. First, the vendor-native raw data were loaded, including the metabolite (water-suppressed) data and unsuppressed water reference data. Second the raw data were pre-processed into averaged spectra. Receiver-coil combination[20] and eddy-current correction[21] of the metabolite data were performed using the water reference data. Individual transients in Siemens and GE data were frequency-and-phase aligned using robust spectral registration[22], while Philips data had been averaged on the scanner. After averaging the individual transients, the residual water signal was removed with a Hankel singular value decomposition (HSVD) filter[23]. For Siemens spectra, an additional pre-phasing step was introduced by modelling the signals from creatine and choline-containing compounds at 3.02 and 3.20 ppm with a double Lorentzian model and applying the inverted model phase to the data. This step corrected a zero-order phase shift in the data arising from the

HSVD water removal, likely because the Siemens water suppression introduced asymmetry to the residual water signal. Finally, the pre-processed spectra were exported in .RAW format.



***Figure 1**. Overview of the MRS analysis pipeline. (A) Pre-processing pipeline implemented in Osprey including 'OspreyLoad' to load the vendor-native spectra, 'OspreyProcess' to process the raw data and to export the averaged spectra. (B) Modelling of the averaged spectra with details of the basis set and parameters of each LCM (LCModel, Osprey, and Tarquin).*

Data modelling

Fully localized 2D density-matrix simulations implemented in the MATLAB toolbox FID-A [24] with vendor-specific refocusing pulse information, timings, and phase cycling were used to generate three vendor-specific basis sets (GE, Philips, and Siemens) including 19 spin systems: ascorbate, aspartate, Cr, negative creatine methylene (-$CrCH_2$), γ-aminobutyric acid (GABA), glycerophosphocholine (GPC), glutathione, glutamine (Gln), glutamate (Glu), water (H_2O), myo-inositol (mI), lactate, NAA, N-acetylaspartylglutamate (NAAG), phosphocholine (PCh), PCr, phosphoethanolamine, scyllo-inositol, and taurine. The -$CrCH_2$ term is a simulated negative creatine methylene singlet at 3.95 ppm, included as a correction term to account for effects of water suppression and relaxation. It is not included in the tCr model, which is used for quantitative referencing.

8 additional Gaussian basis functions were included in the basis set to simulate broad macromolecules and lipid resonances[25] (simulated as defined in section 11.7 of the LCModel manual[26]): $MM_{0.94}$, $MM_{1.22}$, $MM_{1.43}$, $MM_{1.70}$, $MM_{2.05}$, Lip09, Lip13, Lip20. The Gaussian amplitudes were scaled relative to the 3.02 ppm creatine CH_3 singlet in each basis set (details in **Supplementary Information 1**). Finally, to standardize the basis set for each algorithm, basis sets were stored as .mat files for use in Osprey and as .BASIS-files for use in LCModel and Tarquin. In the following paragraphs, each LCM algorithm investigated in this study is described briefly (for details, please refer to the original publications[5,7,11]).

LCModel v6.3

The LCModel (6.3-0D) algorithm[11] models data in the frequency-domain. First, time-domain data and basis functions are zero-filled by a factor of two. Second, frequency-domain spectra are frequency-referenced by cross-correlating them with a set of delta functions representing the major singlet landmarks of NAA (2.01 ppm), Cr (3.02 ppm), and Cho (3.20 ppm). Third, starting values for phase and linebroadening parameters are estimated by modelling the data with a reduced basis set containing NAA, Cr, PCh, Glu, and mI, with a smooth baseline. Fourth, the final modelling of the data is performed with the full basis set, regularized lineshape model and baseline, with starting values for phase, linebroadening, and lineshape parameters derived from the previous step. Model parameters are determined with a Levenberg-Marquardt[27,28] non-linear least-squares optimization implementation that allows bounds to be imposed on the parameters. Metabolite amplitude bounds are defined to be non-negative, and determined using a non-negative linear least-squares (NNLS) fit at each iteration of the non-linear optimization. Amplitude ratio constraints on macromolecule and lipid amplitude, as well as selected pairs of metabolite amplitudes (e.g. NAA+NAAG), are defined as in Osprey and Tarquin. LCModel constrains the model with three additional regularization terms. Two of these terms penalize a lack of smoothness in the baseline and lineshape models using the second derivative operator, preventing unreasonable baseline flexibility and lineshape irregularity. The third term penalizes deviations of the metabolite Lorentzian linebroadening and frequency shift parameters from their expected values.

Osprey

The Osprey (1.0.0) algorithm[5] adopts several key features of the LCModel and Tarquin algorithms. Osprey follows the four-step workflow of LCModel including zero-filling, frequency

referencing, preliminary optimization to determine starting values, and final optimization over the real part of the frequency-domain spectrum. The model parameters are zero- and first-order phase correction, global Gaussian linebroadening, individual Lorentzian linebroadening, and individual frequency shifts, which are applied to each basis function before Fourier transformation. The frequency-domain basis functions are then convolved with an arbitrary, unregularized lineshape model to account for deviations from a Voigt profile. The length of this lineshape model is estimated during the initial referencing step and set to 2.5 times the FWHM estimate. The lineshape model is normalized, so that the convolution does not impact the integral of basis functions.

The spline baseline is constructed from cubic B-spline basis functions, including one additional knot outside either end of the user-specified fit range, as in LCModel. In contrast to LCModel, the baseline curvature is not regularized. Therefore, the baseline knot spacing is set to 0.15 ppm for preliminary modelling step with a reduced basis set and increased to 0.4 ppm for the final full model. Similar to LCModel, model parameters are determined with a Levenberg-Marquardt[27,28] non-linear least-squares optimization algorithm and a NNLS fit to determine the non-negative metabolite amplitudes at each step of the non-linear optimization.

Tarquin

Tarquin (4.3.10)[7] uses a four-step approach in the time domain to model spectra. First, residual water is removed using singular value decomposition. Second, the global zero-order phase is determined by minimizing the difference between the magnitude and the real spectra in the frequency domain. Third, zero-filling to double the number of points and frequency referencing are performed, as in the other algorithms. This step also estimates a starting value for the Gaussian linebroadening used in the fourth step, the final modelling. The model includes common Gaussian linebroadening, individual Lorentzian linebroadening, individual frequency-shifts, and zero- and first-order phase correction factors applied in the frequency domain.

Optimization is performed in the time domain with a constrained non-linear least-squares Levenberg-Marquardt solver, allowing bounds and constraints on the parameters. In addition, the range of time-domain datapoints is limited by removing the first 10 ms of the FID, so as to omit the fast-decaying macromolecule and lipid signals. Finally, the baseline is estimated in the frequency domain by convolving the model residual with a Gaussian filter with a width of 100 points.

192 *Model parameters*

193 The parameters chosen for each tool are summarized in **Figure 1B**. The fit range was limited to
194 0.5 to 4 ppm in all tools to reduce effects of differences in water suppression techniques. For the
195 baseline handling, the default parameters were chosen, i.e. bLineKnotSpace = 0.4 ppm for Os-
196 prey, DKNMNT = 0.15 ppm for LCModel, and an FID range from 10 ms to 50% of the FID for
197 Tarquin.

198

199 Quantification, visualization, and secondary analyses

200 The four major metabolite complexes tNAA (NAA + NAAG), tCho (GPC + PCh), mI, and Glx
201 (Glu + Gln) were quantified as basis-function amplitude ratios relative to total creatine (tCr = Cr
202 + PCr). Since the primary purpose was to compare performance of the core LCM algorithms, no
203 additional relaxation correction or partial volume correction was performed.

204

205 Model visualizations were generated with the *OspreyOverview* module, which allows LCModel
206 and Tarquin results files (.coord and .txt) to be imported. For each algorithm, the visualization
207 includes site-mean spectra, cohort-mean spectra (i.e. the mean of all spectra), and site- and co-
208 hort-mean modelling results (complete model, spline baseline, spline baseline + MM compo-
209 nents, and the separate models of the major metabolite complexes).

210 Three secondary analyses included a linewidth and SNR analysis, as well as the investigation of
211 local baseline power and creatine modelling as potential sources of differences between the algo-
212 rithms (details in **Supplementary Information 2**).

213

214 Data analysis

215 Quantitative metabolite estimates (tNAA/tCr, tCho/tCr, mI/tCr, Glx/tCr) were statistically ana-
216 lyzed and visualized using R[29] in RStudio (Version 1.2.5019, RStudio Inc.). The functions are
217 publicly available[30]. The supplemental materials with MATLAB- and R-files, example LCModel
218 control files (one for each vendor), and Tarquin batch-files for this study are publicly available[31].
219 The results from each LCM algorithm were imported into R with the *spant* package[32].

220 *Distribution analysis*

221 The results are presented as raincloud plots[33] and Pearson's correlation analysis using the
222 *ggplot2* package[34]. The raincloud plots include individual data points, boxplots with median and

223 $25^{th}/75^{th}$ percentiles, a smoothed distribution, and mean ± SD error bars to identify systematic
224 differences between the LC algorithms. In addition, the coefficient of variation (CV = SD/mean)
225 and the mean $\overline{CV} = \frac{(CV_{\mathrm{tNAA}}+CV_{\mathrm{tCho}}+CV_{\mathrm{Ins}}+CV_{\mathrm{Glx}})}{4}$ across all four metabolites of each algorithm are
226 calculated.

227 *Correlation analysis*

228 The correlation analysis featured different levels, including pair-wise correlations between algo-
229 rithms, as well as correlations between baseline power and metabolite estimates of each algo-
230 rithm. The pair-wise correlation on the global level (black R^2), as well as within-vendor correla-
231 tions (color-coded R^2) with different color shades for different sites are reported. Furthermore,
232 mean $\overline{R^2}$ for each pair-wise correlation (e.g. Osprey vs LCModel) and metabolite, estimated by
233 row or column means e.g. $\overline{R^2} = \frac{(R^2_{\mathrm{tNAA}}+R^2_{\mathrm{tCho}}+R^2_{\mathrm{Ins}}+R^2_{\mathrm{Glx}})}{4}$, and a cohort mean $\overline{\mathbf{R}^2}$ (across all pair-
234 wise correlations) are calculated. For the correlations, no correction for multiple testing was ap-
235 plied. The cohort mean $\overline{\mathbf{R}^2}$ was used to identify global associations across all correlation analy-
236 sis, while the mean $\overline{R^2}$ allowed the identification of algorithm-specific (row means) and metab-
237 olite-specific (column means) interactions across all correlation analysis. Associations between
238 the outcome of specific algorithms were identified by the pair-wise correlation analysis (R^2).
239 Vendor-specific effects were identified by differentiating between global level and within-vendor
240 correlations.

241 *Statistical analysis*

242 In the statistical analysis, the presence of significant differences in the mean and the variance of
243 the metabolite estimates was assessed. Global metabolite estimates were compared between al-
244 gorithms with parametric tests, following recommendations for large sample sizes[35]. Differences
245 of variances were tested with Fligner-Killeen's test with a post-hoc pair-wise Fligner-Killeen's
246 test and Bonferroni correction for the number of pair-wise comparisons. Depending on whether
247 variances were different or not, an ANOVA or Welch's ANOVA was used to compare means
248 with a post-hoc paired t-test with equal or non-equal variances, respectively.
249

Results

All 277 spectra were successfully processed, exported, and quantified with the three LCM algorithms; no modelled spectra were excluded from further analysis.

Summary and visual inspection of the modelling results

A site-level averaged summary of the 277 spectra is shown in **Figure 2A**, **B** and **C**, for analyses in LCModel, Osprey, and Tarquin, respectively**.** The averaged data, models and residuals for each of the 25 sites are color-coded by vendor. The cohort-mean of all analyses for each vendor is shown in **Figure 2D**, **E** and **F** (GE, Philips and Siemens, respectively). Data, models and residuals are color-coded by algorithm.



***Figure 2**. Summary of the modelling results. (A–C) site-level averaged residual, data, model, MM model + baseline, baseline and MM model for each LCM algorithm, color-coded by vendor. (D–F) cohort-mean residual, data, model, MM model + baseline, and metabolite models for each vendor, color-coded by LCM algorithm.*

In general, the phased spectra and models agreed well between vendors for all algorithms. Comparing the algorithms, notable differences in spectral features in the estimated baseline models appeared between 0.5 and 1.95 ppm (degree of variability: Osprey > LCModel > Tarquin) and between 3.6 and 4 ppm (degree of variability: LCModel > Osprey > Tarquin) (as shown in **Figure 2A-C**).

Cohort-mean spectra and models agreed well across all vendors and algorithms (**Figure 2D-F**). The greatest differences in the spectral features of the baseline between algorithms occur between 0.5 and 1.95 ppm, with closer agreement between Osprey and Tarquin than with LCModel. The amplitude of the residual over the whole spectral range is highest for Osprey, and similar for Tarquin and LCModel.

NAA linewidth was significantly lower ($p < 0.001$) for Philips (6.3 ± 1.3 Hz) compared to GE (7.3 ± 1.5 Hz), while no differences in the linewidth were found for the other comparisons (Siemens 6.6 ± 2.4 Hz). SNR was significantly higher for Siemens (285 ± 72) compared to both other vendors ($p < 0.001$) and significantly higher ($p < 0.001$) for Philips (226 ± 58) compared to GE (154 ± 37).

Metabolite level distribution

Table 2 *– Metabolite level distribution. Mean, standard deviation and coefficient of variation (CV) of each metabolite-to-creatine ratio, listed by algorithm and vendor as well as global summary values. Asterisks indicate significant differences (adjusted p < 0.01 = ** and adjusted p < 0.001 = *** or ### or ’’’) in the mean (for the metabolite ratios) or the variance (for the CV) compared to the algorithm in the next row (LCModel vs Osprey = ** or ***, Osprey vs Tarquin = ###, and Tarquin vs LCModel = ’’’).*

	[metabolite] / [tCr] (mean ± SD)			
	tNAA	tCho	mI	Glx
GE				
LCModel	1.48 ± 0.12	0.19 ± 0.02	0.85 ± 0.10	1.75 ± 0.25
Osprey	1.47 ± 0.10	0.18 ± 0.02	0.78 ± 0.09	1.42 ± 0.17
Tarquin	1.48 ± 0.11	0.22 ± 0.03	0.57 ± 0.07	2.05 ± 0.22
Philips				
LCModel	1.38 ± 0.10	0.17 ± 0.02	0.81 ± 0.08	1.46 ± 0.14
Osprey	1.50 ± 0.12	0.18 ± 0.02	0.86 ± 0.10	1.34 ± 0.16
Tarquin	1.40 ± 0.12	0.16 ± 0.03	0.60 ± 0.09	1.78 ± 0.19
Siemens				
LCModel	1.52 ± 0.19	0.19 ± 0.02	0.83 ± 0.09	1.65 ± 0.31
Osprey	1.54 ± 0.12	0.19 ± 0.02	0.89 ± 0.06	1.45 ± 0.14
Tarquin	1.50 ± 0.15	0.18 ± 0.03	0.65 ± 0.07	2.04 ± 0.19
global				
LCModel	1.45 ± 0.15***	0.18 ± 0.02	0.83 ± 0.09	1.45 ± 0.15***
Osprey	1.50 ± 0.12###	0.18 ± 0.02	0.84 ± 0.09###	1.50 ± 0.12###
Tarquin	1.46 ± 0.14	0.18 ± 0.04	0.60 ± 0.08’’’	1.93 ± 0.24’’’
	CV (SD/mean)			
	tNAA	tCho	mI	Glx
GE				
LCModel	7.9%	12.9%	11.8%	14.2%
Osprey	6.9%	9.7%	11.1%	11.8%
Tarquin	7.5%	11.7%	11.2%	10.8%
Philips				
LCModel	7.2%	10.6%	9.9%	9.7%
Osprey	8.0%	10.0%	11.8%	11.9%
Tarquin	8.8%	19.8%	15.2%	10.7%
Siemens				
LCModel	12.4%	13.4%	10.8%	18.7%
Osprey	8.0%	11.1%	6.9%	10.0%
Tarquin	10.1%	14.3%	10.5%	9.3%
global				
LCModel	10.0%	13.2%**	10.9%	16.4%***
Osprey	7.8%	10.4%###	11.7%###	11.8%###
Tarquin	9.3%	20.5%’’’	13.6%	12.3%

The tCr ratio estimates and CVs of the four metabolites are summarized in **Table 2**. Distributions and group statistics are visualized in **Figure 3**, with the four rows corresponding the three vendors and a cohort summary across all datasets.



Figure 3. *– Metabolite level distribution. Raincloud plots of the metabolite estimates of each LCM algorithm (color-coded). The four metabolites are reported in the columns, and the three vendors in rows, with a cohort summary in the last row. The coefficient of variation is reported for each distribution, as well as a mean* $\overline{CV}$ *reported in the last column, which is calculated across each row. Asterisks indicate significant differences (adjusted* $p < 0.001$ *= ***).*

Between-algorithm agreement was greatest for the group means and CVs of tNAA and tCho. The cohort-mean CV was lowest for Osprey (10.4%), followed by LCModel (12.6%) and Tarquin (14.0%). Group means and CVs for tNAA are relatively consistent. As a result, the cohort-mean tNAA/tCr was 1.45 ± 0.15 for LCModel, 1.50 ± 0.12 for Osprey, and 1.45 ± 0.14 for Tarquin, with significant differences between Osprey and both other LCM algorithms.

Cohort means for tCho showed a high agreement between all algorithms. The global CV of tCho estimates was significantly higher for Tarquin compared to both other algorithms, and significantly lower for Osprey compared to LCModel. Global tCho/tCr was 0.18 ± 0.02 for LCModel, 0.18 ± 0.02 for Osprey, and 0.18 ± 0.04 for Tarquin.

For mI, group means and CVs were comparable for Osprey and LCModel, while Tarquin estimates were lower by about 25%. Global CVs were significantly lower for Osprey compared to Tarquin, while no significant differences in the CV were found for the other comparisons. Global mI/tCr was 0.83 ± 0.09 for LCModel, 0.84 ± 0.09 for Osprey, and 0.60 ± 0.08 for Tarquin, with significant mean differences between all Tarquin and both other algorithms.

Group means and CVs for Glx were comparable between Osprey and LCModel, while estimates were about 30% higher in Tarquin. Global CV was significantly lower for Osprey compared to both other algorithms. Global Glx/tCr was 1.45 ± 0.15 for LCModel, 1.50 ± 0.12 for Osprey, and 1.93 ± 0.24 for Tarquin, with significant differences between all algorithms. Mean $\overline{CVs}$, estimated by the row-mean, were between 9.0 and 13.8% for all algorithms and vendors.

Correlation analysis: pairwise comparison between LCM algorithms

The correlation analysis for each metabolite and algorithm pair is summarized in **Figure 4**. $\overline{R^2}$ for each algorithm pair and metabolite are reported in the corresponding row and column, respectively.

The cohort-mean $\overline{\mathbf{R}^2}$ = 0.39 suggests an overall moderate agreement between metabolite estimates from different algorithms. The agreement between algorithms, estimated by the row-mean



Figure 4. *Pairwise correlational comparison of algorithms. LCModel and Osprey are compared in the first row, Tarquin and Osprey in the second row, and LCModel and Tarquin in the third row. Each column corresponds to a different metabolite. Within-vendor correlations are color-coded; global correlations are shown in black. The* $\overline{R^2}$ *values are calculated along each dimension of the grid with mean* R^2 *for each metabolite and each correlation. A cohort-mean* $\overline{\boldsymbol{R}^2}$ *value is also calculated across all twelve pair-wise correlations. Asterisks indicate significant correlations (p < 0.01 = ** and p < 0.001 = ***).*

$\overline{R^2}$, was highest for Tarquin-vs-LCModel ($\overline{R^2}$ = 0.43), followed by Osprey-vs-LCModel ($\overline{R^2}$ = 0.38), and Osprey-vs-Tarquin ($\overline{R^2}$ = 0.37).

The agreement between algorithm for each metabolite, estimated by the column-mean $\overline{R^2}$, was highest for tNAA ($\overline{R^2}$ = 0.50), followed by tCho ($\overline{R^2}$ = 0.44), Glx ($\overline{R^2}$ = 0.32), and mI ($\overline{R^2}$ = 0.29). The cohort-mean $\overline{\mathbf{R}^2}$ for each vendor was higher for Siemens ($\overline{\mathbf{R}^2}$ = 0.45) than for GE ($\overline{\mathbf{R}^2}$ = 0.40) and Philips ($\overline{\mathbf{R}^2}$ = 0.40).

While the within-metabolite mean $\overline{R^2}$ (average down the columns in Figure 4) are comparable between vendors, there is substantially higher variability of the R^2 values with increasing granularity of the analysis. **Supplementary Information 3** includes an additional layer of correlations at the site level.

<u>Correlation analysis: baseline and metabolite estimates</u>

The correlation analysis between local baseline power and metabolite estimates for each algorithm is summarized in **Figure 5**. The cohort-mean $\overline{\mathbf{R}^2}$ = 0.10 suggests that overall, there is an association between local baseline power and metabolite estimates, that is weak but statistically significant. The influence of baseline on metabolite estimates differs between metabolites, as reflected by the column-mean $\overline{R^2}$ which was lowest for tCho ($\overline{R^2}$ = 0.04) and tNAA ($\overline{R^2}$ = 0.06), and higher for mI ($\overline{R^2}$ = 0.13) and Glx ($\overline{R^2}$ = 0.18). The global baseline correlations all had negative slope, except for tCho estimates of Tarquin.

The mean $\overline{R^2}$ across metabolites for each algorithm, calculated as the row mean, were low for all algorithms with LCModel ($\overline{R^2}$ = 0.17) showing a greater effect than Tarquin ($\overline{R^2}$ = 0.08) and Osprey ($\overline{R^2}$ = 0.06). Comparing between vendors, the cohort-mean $\overline{\mathbf{R}^2}$ was higher for GE ($\overline{\mathbf{R}^2}$ = 0.15) and Siemens ($\overline{\mathbf{R}^2}$ = 0.14) than for Philips ($\overline{\mathbf{R}^2}$ = 0.05) spectra.



Figure 5. *Correlation analysis between metabolite estimates and local baseline power for each algorithm, including global (black) and within-vendor (color-coded) correlations. The mean* $\overline{R^2}$ *values are calculated along each dimension of the grid for each metabolite and each algorithm. Similarly, a cohort-mean* $\overline{\boldsymbol{R}^2}$ *value is calculated across all twelve pair-wise correlations. Asterisks indicate significant correlations (p < 0.05 = *, p < 0.01 = ** , p < 0.001 = ***).*

Variability of total creatine models



Figure 6. *Variability of tCr models. Mean models +/- standard deviation (shaded areas) are presented column-wise by vendor and color-coded by LCM algorithm. The distribution and CV of the areas under the models are inset.*

Mean tCr model spectra (± one standard deviation) are summarized in **Figure 6** for each vendor and LCM algorithm, along with distribution plots of the area under the model.

The agreement in mean and CV is greatest between Osprey and Tarquin for all vendors, while tCr areas for LCModel appear slightly higher. Differences in water suppression are accounted for with the -$CrCH_2$ correction term, which is not included in the tCr model used for quantitative referencing.

Discussion

We have presented a three-way comparison of LCM algorithms applied to a large dataset of short-TE in-vivo human brain spectra. The aims at the onset were to compare metabolite estimates obtained with different LCM algorithms, as applied in the literature, and to identify potential sources of differences between the algorithms. The major findings are:

- Group means and CVs for tNAA and tCho agreed well across vendors and algorithms. For mI and Glx, group means and CVs were less consistent between algorithms, with a higher degree of agreement between Osprey and LCModel than with Tarquin.
- The strength of the correlations between individual metabolite estimates from different algorithms was moderate. In general, tNAA and tCho estimates from different algorithms agreed better than Glx and mI. With each sub-level of analysis, the variability of correlation strength increased, i.e. correlations grew increasingly variable when calculated separately for each vendor, or even each site.
- Overall, the association between metabolite estimates and the local baseline power was significant, with mI and Glx showing stronger associations than tNAA and tCho, and LCModel showing greater effects than Tarquin and Osprey.

The strong agreement of group means and CVs for metabolites with prominent singlets (tNAA/tCho) and inconsistency for lower-intensity coupled signals (mI/Glx) are in line with previous two-tool comparisons of simulated data [7,15] and in-vivo studies with smaller sample sizes [7,14,16].

While previous work highlighted group means and standard deviations, the between-algorithm agreement of individual metabolite estimates has not been extensively studied. Our results suggest that substantial variability is introduced by the choice of the analysis software itself, indicated by only moderate between-algorithm correlation strength (between-algorithm mean $\overline{R^2}$ <= 0.5 for all investigated metabolites), even for the well-established LCM algorithms LCModel and Tarquin (R^2 between 0.27 and 0.59 for all metabolites). This finding raises concerns about the generalizability and reproducibility of MRS study results. MRS studies typically suffer from low sample sizes (~20 per comparison group is common). Considering the moderate between-tool correlation of individual estimates, it is likely that marginally significant group effects and correlations found with one analysis tool will not be found with another tool, even if the exact same

376 dataset is used. This is exacerbated by the substantial variability of correlation strengths at ven-
377 dor- or even site-level, and is even more likely to be the case for 'real-life' clinical data, given
378 the relatively high quality of the dataset in this study (standardized pre-processing; large sample
379 size; high SNR; low linewidth; young, healthy, cooperative subjects). While two previous studies
380 found that some differences between clinical groups remained significant independent of the
381 LCM algorithm [14,16], this is questionable as a default assumption. The lack of comparability aris-
382 ing from the additional variability originating in the choice of analysis tool is rarely recognized
383 or acknowledged. If choice of analysis tool is a significant contributor to measurement variance,
384 it could be argued that modelling of data with more than one algorithm will improve the
385 robustness and power of MRS studies. It should also be investigated whether the reduction of the
386 degrees of freedom by improving MM and baseline models (e.g. by using acquired MM data)
387 increases between-tool agreement and consistency between sites and vendors.

388 Sources of variance

389 In order to understand the substantial variability introduced by the choice of analysis tool, the in-
390 fluence of modelling strategies and parameters on quantitative results needs to be better under-
391 stood. Previous investigations have shown that, within a given LCM algorithm, metabolite esti-
392 mates can be affected by the choice of baseline knot spacing[36,37], the modelling of MM and lipids
393 [36,38], and SNR and linewidth[39–42]. In this study, we focused on the comparison of each LCM with
394 their default parameters, and observed differences resulting both from the default parameters and
395 from differences in the core algorithm.

396 LCM relies on the assumption that broad background and baseline signals can be separated from
397 narrower metabolite signals. This is true to a limited degree, and the choice of MM and baseline
398 modelling influences the quantification of metabolite resonances[4]. Our secondary analysis of the
399 relationship between baseline power and metabolite estimates showed a stronger interaction for
400 the broader coupled signals of Glx and mI than the singlets. tCho showed the weakest effect, and
401 the three LCMs showed the highest agreement between the MM+baseline models around 3.2
402 ppm. The higher variance of Glx and mI estimates may at least partly be explained by the ab-
403 sence of MM basis functions for frequencies >3 ppm in the model. MM signal must therefore ei-
404 ther be modelled by metabolite basis functions or the spline baseline. Including experimental
405 MM acquisitions into studies may reduce the degrees of freedom of modelling, but introduce
406 other sources of variance, such as age-dependency[43] or tissue composition[38,44]. While consensus

407 is emerging that such approaches are recommended many open questions must be resolved be-
408 fore the recommendations can be broadly implemented[25].
409 For all three LCM algorithms, optimization between the model and the data is solved by local
410 optimization. Algorithms could converge on a local minimum, if the search space of the non-
411 linear parameters is of high dimensionality, or if the starting values of the parameters are far
412 away from the global optimum[45]. The availability of open-source LCM such as Tarquin and Os-
413 prey will allow further investigation of the relationship between optimization starting values and
414 modelling outcomes.
415
416 Since this study focused on reporting tCr ratios, it is important to consider the variance of the
417 creatine model of each algorithm. With MRS only quantitative in a relative sense, separating the
418 variance contribution of the reference signal is a challenge. While mean tCr model areas were
419 slightly higher for LCModel than for Osprey and Tarquin, there was no generalizable observa-
420 tion of lower tCr ratios from LCModel. CVs of the tCr model areas were comparable across
421 LCM algorithms for each vendor. Vendor differences in water suppression of each vendor were
422 accounted for by limiting the analysis range to 0.5 to 4 ppm, and by including a -$CrCH_2$ correc-
423 tion term (omitted from calculations of the tCr ratios and the secondary analysis of the tCr mod-
424 els). The contribution of the reference signal to the variance of metabolite estimates is unclear
425 and hard to isolate. Nevertheless, tCr referencing was preferred in this study, since water refer-
426 encing is likely to add additional tool-specific variance resulting from water amplitude estima-
427 tion.
428
429 Limitations
430 As mentioned in greater detail above, there is currently no widely adopted consensus on the defi-
431 nition of MM basis functions, and measured MM background data are not widely available to
432 non-expert users. To reflect common practice in current MRS applications, the default MM basis
433 function definitions from LCModel were adapted for each algorithm in this study. These basis
434 functions only included MMs for frequencies < 3.0 ppm, which is likely insufficient for the mod-
435 elling of MM signals between 3 and 4 ppm[46], and will have repercussions for the estimation of
436 tCho, mI, and Glx. Second, standard modelling parameters were chosen for each LCM, which
437 ensure a broader comparability to the current literature, but may not be ideal. Third, there is

obviously no ‘gold standard’ of metabolite level estimation to validate MRS results against. The performance of an algorithm is often judged based on the level of variance, but low variance clearly does not reflect accuracy and may indicate insufficient responsiveness of a model to the data. In comparing multiple algorithms, it is tempting to infer algorithms that show a higher degree of correlation in results are more reliable, but it could equally be the case that shared algorithm-based sources of variance increase such correlations. Efforts to use simulated spectra as a gold-standard, including those applying machine learning [47,48], can only be successful to the extent that simulated data are truly representative of in-vivo data. Fourth, another criterion to judge the performance of an algorithm is the residual. For example, a small residual indicates a higher agreement between the complete model and the data for LCModel, it does not infer a better estimation of individual metabolites, and may result from the higher degree of freedom in the baseline of LCModel (higher number of splines) compared to Osprey and Tarquin. This is emphasized by the high agreement of the mean mI models, but lower agreement of the baseline models around 3.58 ppm between LCModel and Osprey. Fifth, this study was limited to the two most widely used algorithms LCModel and Tarquin, as well as the Osprey algorithm that is under ongoing development in our group. While including additional algorithms would increase the general understanding of different algorithms, the complexity of the resulting analysis and interpretation would be overwhelming and beyond the scope of a single publication.

Conclusion

This study presents a comparison of three LCM algorithms applied to a large short-TE PRESS dataset. While different LCM algorithms' estimates of major metabolite levels agree broadly at a group level, correlations between results are only weak-to-moderate, despite standardized pre-processing, a large sample of young, healthy and cooperative subjects, and high spectral quality. The variability of metabolite estimates that is introduced by the choice of analysis software is substantial, raising concerns about the robustness of MRS research findings, which typically use a single algorithm to draw inferences from much smaller sample sizes.

Acknowledgement

This work is supported by NIH grants R01 EB016089 R01 EB023963 R21A G060245. GO receives support from NIH grant K99 AG062230. MP is supported by NIH grants P41EB015909 and R01NS106292.

References

1. Öz G, Alger JR, Barker PB, et al. Clinical Proton MR Spectroscopy in Central Nervous System Disorders. *Radiology*. 2014;270(3):658-679. doi:10.1148/radiol.13130531

2. Wilson M, Andronesi O, Barker PB, et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. *Magn Reson Med*. 2019;82(2):527–550. doi:10.1002/mrm.27742

3. Bottomley P. *Selective Volume Method for Performing Localized NMR Spectroscopy*. Vol 3.; 1985. doi:10.1016/0730-725X(85)90032-3

4. Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts' consensus recommendations. *NMR Bio-med*. 2020;n/a(n/a):e4257. doi:10.1002/nbm.4257

5. Oeltzschner G, Zöllner HJ, Hui SCN, et al. Osprey: Open-source processing, reconstruction & estimation of magnetic resonance spectroscopy data. *J Neurosci Methods*. 2020;343:108827. doi:10.1016/j.jneumeth.2020.108827

6. Juchem C. INSPECTOR - A Tool for Teaching Magnetic Resonance Spectroscopy. In: *26th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)*. Paris, France; 2018.

7. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo 1 H magnetic resonance spectros-copy data. *Magn Reson Med*. 2011;65(1):1–12. doi:10.1002/mrm.22579

8. Poullet J-B, Sima DM, Simonetti AW, et al. An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES. *NMR Biomed*. 2007;20(5):493–504. doi:10.1002/nbm.1112

9. Soher BJ, Semanchuk P, Todd D, Steinberg J, Young K. VeSPA: Integrated applications for RF pulse design, spectral simulation and MRS data analysis. In: *19th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)*. Montreal, Canada; 2011. https://cds.ismrm.org/protected/11MProceedings/files/1410.pdf. Accessed May 19, 2020.

10. Graveron-Demilly D. Quantification in magnetic resonance spectroscopy based on semi-parametric approaches. *Magn Reson Mater Phys Biol Med*. 2014;27(2):113-130. doi:10.1007/s10334-013-0393-4

11. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med*. 1993;30(6):672–679. doi:10.1002/mrm.1910300604

12. Osorio-Garcia MI, Sima DM, Nielsen FU, Himmelreich U, Huffel SV. Quantification of magnetic resonance spectroscopy signals with lineshape estimation. *J Chemom*. 2011;25(4):183-192. doi:10.1002/cem.1353

13. Shen ZW, Chen YW, Wang HY, et al. Quantification of Metabolites in Swine Brain by ^1H MR Spectroscopy Using LCModel and QUEST: A Comparison Study. In: *2008 Congress on Image and Signal Processing*. Vol 5. ; 2008:299-302. doi:10.1109/CISP.2008.478

14. Kossowski B, Orzeł J, Bogorodzki P, Wilson M, Setkowicz Z, P. Gazdzinski S. Follow-up analyses on the effects of long-term use of high fat diet on hippocampal metabolite concentrations in Wistar rats: Comparing Tarquin quantification of 7.0T rat metabolites to LCModel. *Biol Eng Med*. 2017;2(4). doi:10.15761/BEM.1000129

15. Mosconi E, Sima DM, Garcia MIO, et al. Different quantification algorithms may lead to different results: a comparison using proton MRS lipid signals. *NMR Biomed*. 2014;27(4):431-443. doi:10.1002/nbm.3079

16. Scott J, Underwood J, Garvey LJ, Mora-Peris B, Winston A. A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease. *Br J Radiol*. 2016;89(1060):20150979. doi:10.1259/bjr.20150979

17. Považan M, Mikkelsen M, Berrington A, et al. Comparison of Multivendor Single-Voxel MR Spectroscopy Data Acquired in Healthy Brain at 26 Sites. *Radiology*. 2020;295(1):191037. doi:10.1148/radiol.2020191037

18. Mikkelsen M, Barker PB, Bhattacharyya PK, et al. Big GABA: Edited MR spectroscopy at 24 research sites. *NeuroImage*. 2017;159:32–45. doi:10.1016/j.neuroimage.2017.07.021

19. Big GABA repository. Big GABA repository. https://www.nitrc.org/projects/biggaba/. Published 2018. Accessed May 27, 2020.

20. Hall EL, Stephenson MC, Price D, Morris PG. Methodology for improved detection of low concentration metabolites in MRS: Optimised combination of signals from multi-element coil arrays. *NeuroImage*. 2014;86:35-42. doi:10.1016/j.neuroimage.2013.04.077

21. Klose U. In vivo proton spectroscopy in presence of eddy currents. *Magn Reson Med*. 1990;14(1):26–30. doi:10.1002/mrm.1910140104

22. Mikkelsen M, Tapper S, Near J, Mostofsky SH, Puts NAJ, Edden RAE. Correcting frequency and phase offsets in MRS data using robust spectral registration. *NMR Biomed*. July 2020:e4368. doi:10.1002/nbm.4368

23. Barkhuijsen H, de Beer R, van Ormondt D. Improved algorithm for noniterative time-domain model fitting to exponentially damped magnetic resonance signals. *J Magn Reson 1969*. 1987;73(3):553–557. doi:10.1016/0022-2364(87)90023-0

24. Simpson R, Devenyi GA, Jezzard P, Hennessy TJ, Near J. Advanced processing and simulation of MRS data using the FID appliance (FID-A)—An open source, MATLAB-based toolkit. *Magn Reson Med*. 2017;77(1):23–33. doi:10.1002/mrm.26091

25. Cudalbu C, Behar KL, Bhattacharyya PK, et al. Contribution of macromolecules to brain 1H MR spectra: Experts' consensus recommendations. *NMR Biomed Revis*. 2020.

26. Provencher S. LCModel & LCMgui User's Manual. LCModel & LCMgui User's Manual. http://s-provencher.com/pub/LCModel/manual/manual.pdf. Published 2020. Accessed July 15, 2020.

27. Levenberg K. A method for the solution of certain non-linear problems in least squares. *Q Appl Math*. 1944;2(2):164-168. doi:10.1090/qam/10666

28. Marquardt DW. An Algorithm for Least-Squares Estimation of Nonlinear Parameters. *J Soc Ind Appl Math*. 1963;11(2):431-441. doi:10.1137/0111030

29. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2017. https://www.R-project.org/.

30. SpecVis GitHub repository. SpecVis GitHub repository. https://github.com/hezoe100/SpecVis. Published 2020. Accessed May 27, 2020.

31. Zöllner HJ. Comparison of algorithms for linear-combination modelling of short-echo-time magnetic resonance spectra. https://osf.io/3ekq4/. Published June 1, 2020. Accessed June 2, 2020.

32. https://github.com/martin3141/spant. spant GitHub repository. https://github.com/martin3141/spant. Published 2017. Accessed May 27, 2020.

33. Allen M, Poggiali D, Whitaker K, Marshall TR, Kievit RA. Raincloud plots: a multi-platform tool for robust data visualization. *Wellcome Open Res*. 2019;4:63. doi:10.12688/wellcomeopenres.15191.1

34. Wickham H. *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York; 2009. http://ggplot2.org.

35. Fagerland MW. T-tests, non-parametric tests, and large studiesa paradox of statistical practice? *BMC Med Res Methodol*. 2012;12(1):78. doi:10.1186/1471-2288-12-78

36. Marjańska M, Terpstra M. Influence of fitting approaches in LCModel on MRS quantification focusing on age-specific macromolecules and the spline baseline. *NMR Biomed*. November 2019. doi:10.1002/nbm.4197

37. Wenger KJ, Hattingen E, Harter PN, et al. Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1H-MRS. *NMR Biomed*. 2019;32(1):e4027. doi:10.1002/nbm.4027

38. Schaller B, Xin L, Gruetter R. Is the macromolecule signal tissue-specific in healthy human brain? A \textlesssup\textgreater1\textless/sup\textgreater H MRS study at 7 tesla in the occipital lobe. *Magn Reson Med*. 2014;72(4):934–940. doi:10.1002/mrm.24995

39. Bartha R. The Effect of Signal to Noise Ratio and Linewidth On 4T Short Echo Time 1H MRS Metabolite Quantification. *Proc 13th Sci Meet Int Soc Magn Reson Med*. 2005;216(1):2459–2459.

40. Near J. Investigating the effect of spectral linewidth on metabolite measurement bias in short-TE MRS. In: *21th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)*. Milan, Italy; 2014.

41. Wijtenburg SA, Knight-Scott J. The Impact of SNR on the Reliability of LCModel and QUEST Quantitation in 1 H-MRS. In: *17th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)*. ; 2009.

42. Zhang Y, Shen J. Effects of noise and linewidth on in vivo analysis of glutamate at 3 T. *J Magn Reson*. 2020;314. doi:10.1016/j.jmr.2020.106732

43. Marjańska M, Deelchand DK, Hodges JS, et al. Altered macromolecular pattern and content in the aging human brain. *NMR Biomed*. 2018;31(2):e3865. doi:10.1002/nbm.3865

44. Považan M, Strasser B, Hangel G, et al. Simultaneous mapping of metabolites and individual macromolecular components via ultra-short acquisition delay 1H MRSI in the brain at 7T. *Magn Reson Med*. 2018;79(3):1231-1240. doi:10.1002/mrm.26778

45. Poullet J-B, Sima DM, Van Huffel S. MRS signal quantitation: A review of time- and frequency-domain methods. *J Magn Reson*. 2008;195(2):134-144. doi:10.1016/j.jmr.2008.09.005

46. Giapitzakis I-A, Avdievich N, Henning A. Characterization of macromolecular baseline of human brain using metabolite cycled semi-LASER at 9.4T. *Magn Reson Med*. 2018;80(2):462-473. doi:10.1002/mrm.27070

47. Lee HH, Kim H. Deep learning-based target metabolite isolation and big data-driven measurement uncertainty estimation in proton magnetic resonance spectroscopy of the brain. *Magn Reson Med*. 2020;n/a(n/a). doi:10.1002/mrm.28234

48. Lee HH, Kim H. Intact metabolite spectrum mining by deep learning in proton magnetic resonance spectroscopy of the brain. *Magn Reson Med*. 2019;82(1):33-48. doi:10.1002/mrm.27727

Figure Captions

Figure 2. *Overview of the MRS analysis pipeline. (A) Pre-processing pipeline implemented in Osprey including 'OspreyLoad' to load the vendor-native spectra, 'OspreyProcess' to process the raw data and to export the averaged spectra. (B) Modelling of the averaged spectra with details of the basis set and parameters of each LCM (LCModel, Osprey, and Tarquin).*

Figure 2. *Summary of the modelling results. (A–C) site-level averaged residual, data, model, MM model + baseline, baseline and MM model for each LCM algorithm, color-coded by vendor. (D–F) cohort-mean residual, data, model, MM model + baseline, and metabolite models for each vendor, color-coded by LCM algorithm.*

Figure 3. *– Metabolite level distribution. Raincloud plots of the metabolite estimates of each LCM algorithm (color-coded). The four metabolites are reported in the columns, and the three vendors in rows, with a cohort summary in the last row. The coefficient of variation is reported for each distribution, as well as a mean* $\overline{CV}$ *reported in the last column, which is calculated across each row. Asterisks indicate significant differences (adjusted* $p < 0.001$ *= ***).*

Figure 4. *Pairwise correlational comparison of algorithms. LCModel and Osprey are compared in the first row, Tarquin and Osprey in the second row, and LCModel and Tarquin in the third row. Each column corresponds to a different metabolite. Within-vendor correlations are color-coded; global correlations are shown in black. The* $\overline{R^2}$ *values are calculated along each dimension of the grid with mean* R^2 *for each metabolite and each correlation. A cohort-mean* $\overline{\boldsymbol{R}^2}$ *value is also calculated across all twelve pair-wise correlations. Asterisks indicate significant correlations (*$p < 0.01$ *= ** and* $p < 0.001$ *= ***).*

Figure 5. *Correlation analysis between metabolite estimates and local baseline power for each algorithm, including global (black) and within-vendor (color-coded) correlations. The mean* $\overline{R^2}$ *values are calculated along each dimension of the grid for each metabolite and each algorithm. Similarly, a cohort-mean* $\overline{\boldsymbol{R}^2}$ *value is calculated across all twelve pair-wise correlations. Asterisks indicate significant correlations (*$p < 0.05$ *= *,* $p < 0.01$ *= ** ,* $p < 0.001$ *= ***).*

Figure 6. *Variability of tCr models. Mean models +/- standard deviation (shaded areas) are presented column-wise by vendor and color-coded by LCM algorithm. The distribution and CV of the areas under the models are inset.*

Supplementary Material 3. *Facetted pair-wise correlational comparison of algorithms. LCModel and Osprey are compared in the first row, Tarquin and Osprey are compared in the second row, and LCModel and Tarquin are compared in the third row. Each sub-plot (A-D) corresponds to a different metabolite. Within-vendor (bold line with confidence interval) and within-site (thin line) correlations are color-coded. Asterisks indicate significant correlations ($p < 0.01$ = ** and $p < 0.001$ = ***).*

Table Captions

Table 3. *Overview of linear-combination modelling algorithms. The domain (time TD or frequency FD) of modelling and the baseline model approach are specified. *Citations reported from Google Scholar on July 29, 2020.*

Table 4. *Metabolite level distribution. Mean, standard deviation and coefficient of variation (CV) of each metabolite-to-creatine ratio, listed by algorithm and vendor as well as global summary values. Asterisks indicate significant differences (adjusted $p < 0.01$ = ** and adjusted $p < 0.001$ = *** or ### or ''') in the mean (for the metabolite ratios) or the variance (for the CV) compared to the algorithm in the next row (LCModel vs Osprey = ** or ***, Osprey vs Tarquin = ###, and Tarquin vs LCModel = ''').*

Supplementary Material 1. *Properties of the Gaussian functions of the broad macromolecule and lipid resonances included in the basis sets, taken from section 11.7 of the LCModel manual. The amplitude values are scaled relative to the CH_3 singlet of creatine with amplitude 3.*

Supplementary Material

Name	*Frequencies [ppm]*	*FWHM [ppm]*	*Amplitude*
MM09	0.91	0.14	3.00
MM12	1.21	0.15	2.00
MM14	1.43	0.17	2.00
MM17	1.67	0.15	0.20
MM20	2.08	0.15	1.33
	2.25	0.20	0.33
	1.95	0.15	0.33
	3.00	0.20	0.40
Lip09	0.89	0.14	3.00
Lip13a	1.28	0.15	2.00
Lip13b	1.28	0.089	2.00
Lip20	2.04	0.15	1.33
	2.25	0.15	0.67
	2.80	0.20	0.87

Supplementary Material 1. *Properties of the Gaussian functions of the broad macromolecule and lipid resonances included in the basis sets, taken from section 11.7 of the LCModel manual. The amplitude values are scaled relative to the* CH_3 *singlet of creatine with amplitude 3.*

Supplementary Material 2 – Overview plot and secondary analyses

Details on the creation of the visual overview plot

As in the default visualizations for the LCModel and Tarquin software interfaces, inverse phase estimates were applied to the spectra and final models. For the visualization, spectra were normalized to the amplitude of the 3-ppm creatine singlet, and a DC offset was added to each site mean spectrum to align the mean frequency-domain amplitude between 1.85 and 4.0 ppm, to aid visual comparison between algorithms and sites.

Details on the three secondary analyses:

1. To investigate potential vendor differences in linewidth and SNR based on the different export formats of the data, NAA linewidth and SNR were investigated.
2. To investigate potential interactions between baseline power and metabolite estimates unbiased by DC offsets, the MM + baseline models were first aligned vertically according to the frequency-domain minimum of the acquired spectra between 2.66 and 2.7 ppm (i.e. between the aspartyl signals, which is the region with the highest consistency between the baseline models). Baseline models were normalized to the frequency-domain amplitude of each metabolite spectrum between 2.9 and 3.1 ppm to account for differences in the scaling of the model outputs of LCModel and Tarquin. Baseline power beneath each major metabolite was then defined as the range-normalized integral of the baseline model between 1.9 and 2.1 ppm for the tNAA baseline; 3.1 and 3.3 ppm for the tCho baseline; 3.33 and 3.75 ppm for mI; and 1.9 to 2.5 ppm and 3.6 to 3.8 ppm for the Glx baseline.
3. The contribution of variance in modelling of the creatine reference signal to metabolite ratios was also investigated. To this end, each individual total creatine model (Cr + PCr) was normalized to the frequency-domain amplitude of each metabolite spectrum between 1.9 and 2.1 ppm to account for differences in the scaling of the total creatine model outputs of LCModel and Tarquin. Finally, the integral over the individual creatine model was calculated.



Supplementary Material 3. *Facetted pair-wise correlational comparison of algorithms. LCModel and Osprey are compared in the first row, Tarquin and Osprey are compared in the second row, and LCModel and Tarquin are compared in the third row. Each sub-plot (A-D) corresponds to a different metabolite. Within-vendor (bold line with confidence interval) and within-site (thin line) correlations are color-coded. Asterisks indicate significant correlations (p < 0.01 = ** and p < 0.001 = ***).*